References

W
Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis. 2013;57(1):77-84.
Wohl DA, Allmon AG, Evon D. Financial incentives for adherence to hepatitis C virus clinical care and treatment: a randomized trial of two strategies. Open Forum Infect Dis. 2017;4(2):ofx095. doi:10.1093/ofid/ofx095.
Wong RJ, Nguyen MT, Trinh HN, et al. Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the US. J Viral Hepatitis. 2017;24(1):17-21.
Wong KA, Worth A, Martin R, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57(12):6333-6340.
Wong JB, Cohen JT. Cost-effective but bad for health? Hepatitis C treatment, moral hazard, and opportunity cost. Clin Gastroenterol Hepatol. 2017;15(6):838-840.
Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med. 2019;380(17):1606-1617. doi:10.1056/NEJMoa1812406.
Wu DB, Jiang W, Wang YH, et al. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. J Viral Hepat. 2019;26(3):316-322. doi:10.1111/jvh.13033.
Wyles DL, Brau N, Kottilil S, et al. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study Abstract PS104. In: International Liver Congress 2016. April 13-17. International Liver Congress 2016. April 13-17. Barcelona, Spain; 2016.
Wyles D, Mangia A, Cheng W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir [Epub ahead of print]. Antiviral Therapy. 2017.
Wyles DL, Mangia A, Cheng W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018;23(3):229-238.
Wyles D, Poordad F, Wang S, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial: viral hepatitis. Hepatology. 2018;67(2):514-523.
Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714-725.
Wyles D, Bräu N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of HCV in patients coinfected with HIV-1: an open-label, phase 3 study. Clin Infect Dis. 2017;65(1):6-12.
Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70(5):1019-1023. doi:10.1016/j.jhep.2019.01.031.
Wyles DL, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61(6):1793-1797.
Top